Clin2
NCT06731868Possibly a fitRecruiting

Study of an experimental tablet for tardive dyskinesia

Tardive Dyskinesia (TD)

Treatments studied

Part of Brain & nervous system clinical trials.

This study tests an experimental once-daily tablet for moderate-to-severe tardive dyskinesia, a condition causing uncontrollable repetitive movements. It aims to see if the drug is safe and reduces these symptoms over time.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
120 people
Ages
18 years to 64 years
Study type
Interventional

Who can take part

  • You are between 18 and 65 years old.
  • You have been diagnosed with tardive dyskinesia (uncontrollable movements) caused by a medication, and have had symptoms for at least 3 months.
  • You have a stable mental health condition (like schizophrenia, bipolar disorder, or depression), and your medications for that condition have not changed in the last month.
  • Your tardive dyskinesia symptoms are moderate to severe (based on a doctor's assessment).
  • You are willing to avoid pregnancy or fathering a child during the study and for 1 month after the last dose.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07365462Recruiting· Phase 2
Study of NBI-1065890 for tardive dyskinesia in adults

This trial tests whether an oral medication, NBI-1065890, can reduce the involuntary muscle movements caused by long-term use of antipsychotic drugs. It is for adults with moderate to severe tardive dyskinesia who also have a stable mental health condition like schizophrenia or bipolar disorder.

Bryant, Arkansas
NCT06218719Not yet recruiting
Study of patient engagement in untreated tardive dyskinesia

This study looks at how people with tardive dyskinesia (a movement disorder) who have never been treated engage with their care. It aims to understand their patterns and experiences, which may help improve future treatment approaches.

San Francisco, California
NCT07725562Recruiting· Phase 2/Phase 3
Testing a new pill for early-to-mid-stage Parkinson's disease

This trial tests a new tablet (VG081821AC) for people with early-to-mid-stage Parkinson's disease who have not recently used levodopa. The goal is to see if it can improve movement symptoms safely.

Beijing
NCT07173920Recruiting
Precision rTMS for tardive dyskinesia motor symptoms

This study tests whether a non-invasive brain stimulation technique called repetitive transcranial magnetic stimulation (rTMS), targeted precisely using brain imaging, can safely reduce the involuntary movements caused by some psychiatric medications. If you have tardive dyskinesia, this treatment might help improve your motor symptoms.

Beijing
NCT07105111Recruiting· Phase 4
Valbenazine for tardive dyskinesia after other treatment

This study tests if valbenazine helps adults with tardive dyskinesia whose symptoms continue even after taking or stopping another similar medication. Tardive dyskinesia involves uncontrollable movements from long-term use of certain mental health drugs.

Bryant, Arkansas
NCT07142044Recruiting· Phase 1/Phase 2
Testing EC5026 for Parkinson's disease

This study tests a new oral medication called EC5026 for Parkinson's disease. It aims to see if the drug is safe and if it might help control symptoms when added to your current levodopa treatment.

Sacramento, California

Hear when a new Tardive Dyskinesia (TD) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.